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Hepatocyte transplantation is a promising alternative therapy for the treatment of hepatic failure, hepatocellular 
deficiency, and genetic metabolic disorders. Hypothermic preservation of isolated human hepatocytes is potentially 
a simple and convenient strategy to provide on-demand hepatocytes in sufficient quantity and of the quality required 
for biotherapy. In this study, first we assessed how cold storage in three clinically safe preservative solutions (UW, 
HTS-FRS, and IGL-1) affects the viability and in vitro functionality of human hepatocytes. Then we evaluated 
whether such cold-preserved human hepatocytes could engraft and repopulate damaged livers in a mouse model 
of liver failure. Human hepatocytes showed comparable viabilities after cold preservation in the three solutions. 
The ability of fresh and cold-stored hepatocytes to attach to a collagen substratum and to synthesize and secrete 
albumin, coagulation factor VII, and urea in the medium after 3 days in culture was also equally preserved. Cold-
stored hepatocytes were then transplanted in the spleen of immunodeficient mice previously infected with adeno-
viruses containing a thymidine kinase construct and treated with a single dose of ganciclovir to induce liver injury. 
Engraftment and liver repopulation were monitored over time by measuring the blood level of human albumin and 
by assessing the expression of specific human hepatic mRNAs and proteins in the recipient livers by RT-PCR and 
immunohistochemistry, respectively. Our findings show that cold-stored human hepatocytes in IGL-1 and HTS-FRS 
preservative solutions can survive, engraft, and proliferate in a damaged mouse liver. These results demonstrate the 
usefulness of human hepatocyte hypothermic preservation for cell transplantation.
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INTRODUCTION
Currently, liver transplantation is the gold standard 
treatment for hepatic failure, hepatocellular deficiency, 
and genetic metabolic disorders. However, this invasive 
procedure is expensive, associated with high morbidity, 
and is limited by the shortage of transplantable organs. 
Biotherapy, such as the use of a bioartificial liver or hepa-
tocyte transplantation, could be an alternative for transient 
or permanent liver metabolic support. Hepatocytes iso-
lated from livers that are not suitable for orthotopic trans-
plantation could provide an additional chance for patients 
on waiting lists and a unique opportunity for those who 
are not eligible for liver transplant. The development of 
approaches for hepatocyte preparation in specialized 
centers with the aim of providing on-demand sufficient 
amounts of good quality hepatocytes could broaden the 
scope of these therapies (42). As the hepatocyte source 
(i.e., donors) is inherently unpredictable, it is necessary 
to establish the best strategy to identify and prepare the 
recipient patients and to handle and dispatch the cells to 
be injected. Hepatocyte cryopreservation and banking is 
theoretically the most adapted practical solution. Freezing/
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thawing protocols have been considerably improved over 
the years, and now cryopreserved hepatocytes are viable, 
with some metabolic activities close to those of fresh hepa-
tocytes (e.g., CYP) for at least a short period after thawing 
(28,44). However, poor attachment to culture substrates is 
often reported, thus limiting their long-term in vitro use 
and questions their ability to adhere to the hepatic sinusoi-
dal endothelium after transplantation (24,47,49). Indeed, 
there is evidence that cryopreserved hepatocytes are less 
efficient than fresh hepatocytes for transplantation (9,33). 
Alternatively, freshly isolated hepatocytes could be cold 
stored in conditions similar to those used for liver preserva-
tion before transplantation (17,19,30,36,39). This approach 
has been widely explored in experimental settings using 
different organ preservative solutions or defined culture 
media and isolated (2,34,37,40,41) or cultured hepatocytes 
(8,26,39), mainly of animal origin. Most of these studies 
focused on the recovery of the cell metabolic capacities 
after rewarming, with the aim of providing a convenient 
cell source for in vitro drug discovery platforms. To our 
knowledge, the engraftment and repopulation of a dam-
aged liver by cold-stored human hepatocytes has never 
been tested. We thus studied the impact of hypothermic 
preservation in three clinically safe (i.e., drug-agency 
approved) and animal product-free preservative solutions 
on the viability and in vitro functionality of human hepa-
tocytes and also after transplantation in mice with liver 
damage (32). Hypothermic preservation slows down cell 
metabolism and leads to structural membrane damage and 
reduction of the ATP intracellular pool (16,30,46); there-
fore, different solutions have been elaborated to counteract 
these problems. For this study we chose three cold storage 
solutions designed for use in organ transplantation (13). 
The University of Wisconsin (UW) solution was devel-
oped in the late 1980s to prevent cell swelling, intracellular 
acidosis, injury from oxygen-free radicals, and to maintain 
the ATP levels (45). Since then, it has become the standard 
solution for the preservation of most organs for transplan-
tation and also of many cell types in suspension, including 
human hepatocytes shipped for transplantation in clinical 
trials (15,19). It is now considered as the reference for 
clinical applications. Hypothermosol-FRS (HTS-FRS) is 
an improved formulation of the intracellular-like solution 
Hypothermosol (6) that suppresses free radical formation 
in cells undergoing prolonged hypothermic preservation 
(29) and preserves human hepatocyte integrity and metab-
olizing functions (36). We also included Institut Georges 
Lopez 1 (IGL-1), another organ preservative solution that 
contains polyethylene glycol (PEG), as colloid, and has a 
high extracellular sodium/potassium ratio. These features 
should improve liver preservation (4). IGL-1 was found to 
be as efficient and safe as UW while less expensive (10); 
however, it has never been used for cold preservation of 
isolated human hepatocytes.
MATERIALS AND METHODS
Chemicals
Culture media Ham-F12 and William’s medium E, 
additives, and collagenase type IV were purchased from 
Sigma-Aldrich (Saint-Quentin Fallavier, France), fetal calf 
serum from Lonza (Levallois-Perret, France), and cytokines/
growth factors from Peprotech (Neuilly sur Seine, France). 
Hepatocytes in suspension were preserved in IGL-1 solu-
tion (Institut Georges Lopez, Lissieu, France), University 
of Wisconsin solution (UW; VIASPAN; Bristol-Myers 
Squibb, Rueil Malmaison, France), or HTS-FRS (BioLife 
Solutions Inc., Bothell, WA, USA).
Human Hepatocyte Isolation
Liver samples were obtained either after resection for 
medical reasons (primary tumor or metastasis) or from 
donors when the liver was considered unsuitable for organ 
transplantation. The use of human liver tissues to pre-
pare hepatocytes for research purposes was approved by 
the French National Ethics Committees and local legal 
instances. Informed consent was obtained from each patient 
or family prior to surgery. Information on the donors of the 
livers used in this study is shown in Table 1.
Hepatocytes were isolated by using a two-step perfusion 
protocol and cultured as described previously by our labo-
ratory (7,11,14,38). Briefly, several veins apparent on the 
cut edge of the lobectomy were used for sequential perfu-
sions with a washing buffer, with a calcium-chelating buffer 
made according to Pichard et al. (38), and then with a col-
lagenase solution. After gentle disruption of the tissue and 
filtration, the post-collagenase homogenate was centrifuged 
at low speed (50 × g for 5 min) to pellet the hepatocytes. 
Hepatocytes were then resuspended in “short-term culture 
medium” (38) supplemented with 2% heat-inactivated 
fetal calf serum, and seeded at 2.6 × 105 viable cells/cm2 on 
collagen type I-coated wells (Becton Dickinson, Pont De 
Claix, France). After overnight attachment, the medium 
Table 1. Characteristics of the Human Liver Donors
Liver Identity Sex Age Pathology
Liver 1 F 25 Primary hepatic neuroendocrine 
tumor
Liver 2 F 67 Metastasis from colorectal 
carcinoma
Liver 3 F 39 Metastasis from melanoma 
carcinoma
Liver 4 M 61 Metastasis from colorectal 
carcinoma
Liver 5 M 52 Liver donor organ
Liver 6 H 66 Metastasis from colorectal 
carcinoma
Liver 7 F 40 Metastasis from colorectal 
carcinoma
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and unattached cells were removed, and fresh “long-term 
medium” (38) was added. All experiments were carried out 
in duplicate.
Cold Storage
Hepatocytes were resuspended at the indicated con-
centrations in the preservative solutions in 50-ml polycar-
bonate tubes (Becton Dickinson) and left undisturbed for 
12, 24, 48, or 96 h at 2–6°C. At the different time points, 
cells in preservative solutions were diluted with four vol-
umes of “short-term culture medium,” washed once again 
with 50 ml “short-term culture medium,” and classically 
centrifuged at 200 × g for 5 min before seeding.
Cell Viability
Viability was estimated based on the trypan blue exclu-
sion method. After cold storage, hepatocytes in suspen-
sion were washed twice in “short-term culture medium” 
(38) and incubated at room temperature with 0.4% trypan 
blue (Invitrogen, Cergy Pontoise, France) for 5 min. For 
each sample, the percentage of viable cells was calculated 
in duplicate.
Cell Attachment Measurement
After cold storage, hepatocytes were washed in “short-
term culture medium” and seeded at the same concen-
tration as freshly isolated hepatocytes (FIH) (plated at 
a density calculated based on their viability before cold 
storage). Their attachment was estimated by measuring 
the total amount of proteins recovered after overnight 
plating. Wells were washed twice with PBS (Invitrogen) 
to remove unattached cells and medium, and then cells 
were detached and lysed in reporter lysis buffer (Promega, 
Charbonnieres, France) through three freezing/thawing 
cycles. Protein concentration was determined using the 
bicinchoninic acid (BCA) method (Interchim, Montluçon, 
France) according to the manufacturer’s recommenda-
tions. Absorbance at 562 nm was measured using a Mithras 
LB940 microplate reader (Berthold Technologies, Thoiry, 
France), and the total protein concentration per well was 
calculated and expressed as the percentage of the protein 
concentration of freshly isolated hepatocytes.
RNA Analysis by RT-PCR
Total RNA was extracted from human hepatocytes 
(primary cultures) or mouse tissues using the TRIzol 
reagent, according to the manufacturer’s recommenda-
tions (Invitrogen), and 500 ng of total RNA was reverse 
transcribed using random hexaprimers and the MMLV 
Reverse Transcriptase Kit (Invitrogen). Primer sequences 
are in Table 2. When possible, primer pairs were designed 
from different exons to avoid false-positive results in case 
of contamination by genomic DNA.
Quantitative PCR was performed using the Roche 
Molecular Biochemicals Light Cycler system (Roche 
Diagnostic, Meylan, France) with the following program: 
Table 2. Sequences of Primer Pairs Used for Quantitative and Semiquantitative 
RT-PCR Analysis
Experiment/Genes Primer Sequences
Phenotype (quantitative RT-PCR)
C/EBPa AGGGACTTGGGGCTTGGAAC
GACCCCCATCGCAGTGAGTT
C/EBPa GCCCTCGCAGGTCAAGAGCA
TTGAACAAGTTCCGCAGGGTG
HNF1a CCAGCATCCCAGCAGATCCT
GTGTCCATGGCCAGCTTGTG
HNF4a CGCAGATGTGTGTGAGTCCA
CAGTGCCGAGGGACAATGTA
RPLP0 TCGACAATGGCAGCATCTAC
GCCTTGACCTTTTCAGCAAG
Transplantation (semiquantitative RT-PCR)
hAAT CTTTGAAGTCAAGGACACCG
GCTGAAGACCTTAGTGATGC
hAlbumin ACTTCGGGATGAAGGGAAGGC
CATCATTTTCCACTTCGGCAATG
hCPS1 GTTGTCTGAACCAAGCAGCA
CGCAGTGTGCGGATACTAGA
h/mRPLP0 GGCAAGAACACCATGATGCG
CGGACACCCTCCAGAAAGCGA
hRPLP0 TCGACAATGGCAGCATCTAG
GCCTTGACCTTTTCAGCAAG
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one step at 95°C for 10 min, 55 cycles of denaturation 
at 95°C for 15 s, annealing at 65°C for 15 s, elonga-
tion at 72°C for 15 s. The amplification specificity was 
verified by determining the product melting curve. 
Relative expression values were calculated with the 
LightCycler480 software (Roche Diagnostics) and nor-
malized to the expression of ribosomal protein, large, P0 
(RPLP0). RNA from human muscle cells (kindly pro-
vided by Dr. G. Carnac, INSERM U1046, Montpellier, 
France) was included as negative control.
Human liver chimerism in transplanted mice was ana-
lyzed by semiquantitative PCR using the Taq Platinum 
set (Invitrogen) and a Techne TC-512 gradient thermo-
cycler (IMLAB, Lille, France) with the following pro-
gram: one step at 94°C for 2 min, cycles of denaturation 
at 94°C for 30 s, annealing at 60°C for 30 s, and elonga-
tion at 72°C for 30 s, and final step at 72°C for 5 min. 
Primers are listed in Table 2. PCR products were visual-
ized under UV light after migration in 2% agarose gels 
containing the SyberSafe DNA gel stain (Invitrogen). 
The percentage of chimerism was evaluated using RNA 
samples in which increasing concentrations of human 
liver RNA (from 1% to 100%) were mixed with mouse 
liver RNA. The species specificity and efficiency of all 
primers (including the h/m RPLP0 forward primer that 
exhibits one mismatch toward human RPLP0 mRNA) 
were previously validated using mouse and human liver 
cDNA as templates.
Quantification of Human Albumin, Coagulation Factor 
VII, and Urea Production and Secretion
Human albumin in the supernatants of hepatocytes 
or in the serum of chimeric mice following blood sam-
pling from the facial vein was measured using a sandwich 
ELISA assay according to the manufacturer’s instructions 
(Bethyl Laboratory, Montgomery, TX, USA). Human albu-
min concentration was calculated by nonlinear regression 
analysis with the GraphPad Prism 5 software (GraphPad 
Software Inc., La Jolla, CA, USA).
We adapted a previously described ELISA assay 
(Diagnostica Stago, Asnieres, France) (7) to quantify 
the amount of coagulation factor VII in the hepatocyte 
culture supernatant. The culture medium was used as a 
negative control.
Spontaneous production and secretion of urea by hepa-
tocytes was quantified using the QuantiChrom Urea Assay 
Kit (Gentaur, Paris, France), a colorimetric test.
All these analyses were performed in duplicate, and 
the values in hepatocyte supernatants were normalized 
to the amount of total protein extracted from the same 
well and quantified with the BCA method (Interchim, 
Montluçon, France).
Liver Damage Induction and Human 
Hepatocyte Transplantation
We used, with some minor modifications, a recently 
described mouse model in which, following drug-induced 
liver damage, the liver can be efficiently repopulated by 
xeno geneic hepatocytes (3,32). Male Balb/C Rag2tm1Fwa 
Cd3gtm1Amk mice (4–6 weeks old, bred at CIMA, Pamplona, 
Spain) were intravenously inoculated with 5 × 109 PFU 
of recombinant adenoviruses expressing herpes simplex 
virus thymidine kinase (AdTk). In these mice, liver dam-
age is characterized by inflammation accompanied by 
increased hepatocyte size and enlarged nuclei and pro-
vides a growth advantage for transplanted human hepato-
cytes. The AdTk-GCV effect is maintained for 10 weeks 
and then is progressively resolved, as indicated by regen-
erative nodules (32). As soon as the human liver perfusion 
was planned, a single dose of 50 mg/kg ganciclovir (GCV; 
Roche) was intraperitoneally administered to induce sub-
acute liver damage. Human hepatocytes were isolated at 
the production site (Montpellier, France) and were cold 
preserved in HTS-FRS or IGL-1 at 1 × 106 cells/ml on ice 
during shipment to the transplantation site (Pamplona, 
Spain). Thirteen to 15 h after isolation, 1.5 × 106 viable 
human hepatocytes suspended in 100 µl PBS were inocu-
lated in the spleen of mice. Freshly isolated hepatocytes 
were not available. As cultured human hepatocytes were 
previously shown to be a suitable source of cells for the 
generation of chimeric livers in this model (32), hepa-
tocytes from the same donor were cultured in long-term 
medium for 7 days and were transplanted in a group of 
mice used as controls.
FACING PAGE
Figure 1. Impact of cold preservation on human hepatocyte viability and attachment. Different concentrations (0.1, 1, 10, and 25 × 106 cells/
ml) of human hepatocytes were preserved in suspension at 2–8°C using different organ preservation solutions (IGL-1, HTS-FRS, and 
UW) for 16 h. (A) Cell viability was then assessed by using the trypan blue exclusion method (freshly isolated hepatocytes, FIH). 
(B) Hepatocytes were then seeded on collagen type I-coated plates according to their viability before hypothermic preservation, and 
their morphology and confluence were visualized by phase contrast microscopy after 16 h in culture. (C, D) Hepatocytes were pre-
served in suspension (1 × 106 cells/ml) at 2–8°C in the different organ preservation solutions for up to 4 days. At different time points 
(12, 24, 48, 96 h) cells were washed, and (C) their viability was assessed by using the trypan blue exclusion method, and (D) their 
attachment capacity was evaluated by seeding on collagen type I-coated plates according to their viability before hypothermic preser-
vation and by quantifying the total protein amount per well after 16 h in culture. Results are expressed as the percentage of the value 
measured in cells plated immediately after isolation (time 0). Statistical analysis was performed using an ANOVA followed by the 
Dunnett’s post hoc test multiple group comparison, with UW value as a reference (*p < 0.05). Scale bar: 100 µm.
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Then animals received intravenously 100 µl of human 
AB serum (Sigma-Aldrich) and were treated with antibi-
otics at 25 mg/ml in drinking water (enrofloxacin; Bayer 
HealthCare, Barcelona, Spain) for 1 week. Blood was 
collected by retro-orbital bleeding once per week, and 
cell engraf tment was followed by quantifying serum 
human albumin (ELISA assay; Bethyl Laboratories Inc.), 
starting at 3 weeks posttransplantation when the injected 
human serum was cleared. The serum levels of alanine 
and aspartate transaminase (ALT, AST) in transplanted 
mice were quantified using a Cobas C311 analyzer 
(Roche). The study protocol was approved by the Animal 
Experimentation Ethics Committee of the University of 
Navarra, Spain (permit Nos. 041-07 and 095-09).
Immunohistochemistry
Immunohistochemical staining was performed using 
the EnVisionTM+ System (Dako, Glostrup, Denmark) 
according to the manufacturer’s recommendations. Paraf-
fin liver sections (3 µm thick) were sliced, dewaxed, and 
hydrated, and some of them were stained with hematoxy-
lin (Panreac, Catelar del Vallès, Spain) and eosin (H&E) 
(Merck, Darmstadt, Germany) for routine histology. If nec-
essary, heat-induced antigen retrieval (AR) was performed 
by incubating sections at 95°C in 0.01 M Tris-1 mM EDTA 
buffer (pH = 9) (Sigma-Aldrich) in a Pascal pressure cham-
ber (S2800; Dako) for 30 min. Proteolytic-induced AR 
was performed by incubating sections in 20 µg/ml protei-
nase K (Sigma-Aldrich) at 37°C for 30 min. Endogenous 
peroxidase was blocked with 3% H2O2 (Panreac) in deion-
ized water for 10 min. Sections were washed in TBS-0.05% 
Tween 20 (TBS-T) (Fluka, Madrid, Spain) and incubated 
with primary antibodies [anti-hCK-18, 1:100; M7010 
(Dako); anti-albumin, 1:8,000 (Bethyl Laboratories)] at 4°C 
overnight. After rinsing in TBS-T, sections were incubated 
with the relevant secondary antibodies (Dako). Peroxidase 
activity was revealed using DAB+ (K3468; Dako), and sec-
tions were lightly counterstained with Harris hematoxylin 
(Panreac). Finally, they were dehydrated in a graded series 
of ethanol, cleared in xylene, and mounted in DPX (Sigma-
Aldrich). Slides were scanned (Montpellier RIO Imaging 
facilities, INM Montpellier, France) using a Nanozoomer 
Slide Scanner (Hamamatsu Photonics, Massy, France), and 
virtual slides were viewed using the NDP.view software 
(Hamamatsu Photonics).
Statistical Analysis
Experiments on each liver were carried out in dupli-
cate. Results were expressed as the mean ± SEM. One-
way repeated measures analysis of variance (ANOVA) 
followed by the Dunnett’s post hoc test multiple group 
comparison was used to analyze group differences. Data 
were analyzed by GraphPad Prism software version 5 
(GraphPad Software Inc.). Values of p < 0.05 were con-
sidered significant (p < 0.05, p < 0.01, p < 0.001).
RESULTS
Impact of Hypothermic Preservation on Viability, 
Morphology, and Attachment of Human Hepatocytes
To determine the optimal cold-storage conditions for 
human hepatocytes, first we assessed the effect of the con-
centration at which cells were cold stored on their viability. 
To this aim, human hepatocytes were stained with trypan 
blue after 16 h of cold storage in three different preserva-
tive solutions (UW, IGL-1, and HTS-FRS). Overall, cold 
storage reduced cell viability compared to freshly isolated 
hepatocytes (FIHs) (Fig. 1A), and the deleterious effect 
was strongest (viability around 40%) at the lowest cell 
concentration (0.1 × 106 cell/ml). At intermediate cell con-
centrations (1–10 × 106/ml), viability ranged from 48% to 
62%, depending on the storage solutions. IGL-1 solution 
allowed a slight but significantly better recovery of viable 
human hepatocytes than UW. The trypan blue exclusion 
method is based on cell membrane integrity and does not 
portend cell functionalities. Conversely, cell attachment to 
a substratum is an energy-demanding process indicative of 
cell vitality. Cell attachment was thus assessed in parallel 
to viability measurements, assuming that hepatocytes that 
attach and spread on the substrate are viable and functional. 
Hepatocytes that had been cold preserved in suspension at 
different concentrations (see Fig. 1A) for 16 h were thus 
seeded on collagen type I-coated plates at a density calcu-
lated based on their viability before cold storage (i.e., FIH 
viability). Their ability to form a monolayer was assessed 
by phase contrast microscopy after overnight culture. 
Hepatocytes exhibited the same characteristic polygonal 
FACING PAGE
Figure 2. Phenotype and functionality of human hepatocytes cultured after hypothermic preservation. Hepatocytes were seeded on 
collagen type I-coated dishes directly after isolation (FIH) or after cold preservation in suspension in the different solutions for 12 or 
24 h and cultured for 3 days. (A) The mRNA levels of hepatic genes encoding liver-enriched transcription factors (HNF1a, HNF4a, 
C/EBPa, and C/EBPb) were quantified by qRT-PCR and expressed as the percentage of their expression in FIHs. (B) Hepatocyte 
synthetic functions were assessed by quantifying the secretion of albumin, coagulation factor VII, and urea in the medium. Statistical 
analysis was performed using an ANOVA followed by the Dunnett’s post hoc test multiple group comparison, with FIH value as a 
reference (*p < 0.05).
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morphology before and after cold storage in the three 
solutions (Fig. 1B), and cell confluence varied depending 
on the storage conditions (cell concentration and solu-
tion), as observed for cell viability (Fig. 1A). Based on 
these results and on literature data (36), for the subsequent 
experiments, hepatocytes were cold stored in suspension 
at a concentration of 1 × 106 cells/ml. We then examined 
the impact of the cold storage duration on cell viability and 
attachment (Fig. 1C). For all hepatocyte samples (isolated 
from three different livers with viabilities of 78%, 95%, 
and 84%), cell viability declined progressively with the 
storage time (from 72% after 12 h down to 35% after 96 
h of storage) in all solutions. No difference was observed 
concerning the three cold storage solutions, except after 
24 h of hypothermic preservation when cells stored in 
IGL-1 or HTS-FRS showed a significantly better viability 
than cells preserved in UW. Finally, human hepatocytes 
were seeded on collagen type I-coated plates before and 
after cold storage, and plating efficiency was evaluated 
16 h later by quantifying the total protein amount per 
well (Fig. 1D). As with cell viability, the cell attachment 
declined progressively over storage time, from 100% after 
12 h down to 13% after 96 h of cold storage, but without 
any significant difference between the three preservative 
solutions. The difference observed between changes in 
viability and attachment can be explained by the fact that 
cells with little membrane damage may be stained blue, but 
are still viable and have the potential to repair and recover. 
Overall, this experiment indicates that viable hepatocytes 
after cold storage in the three preservative solutions retain 
their adhesive properties.
Phenotype and Functionality of Human Hepatocytes 
After Cold Preservation
The deleterious effect of hypothermia/hypoxia, such as 
apoptosis and mitochondrial dysfunction, can be revealed 
and/or amplified during the rewarming period (12,39,43). 
A viability of 60% is the consensual acceptable limit for 
the use of isolated hepatocytes in clinical settings; thus, 
we were mostly interested in analyzing the phenotype 
of hepatocytes selected for this criteria. Therefore, the 
functionality of human hepatocytes after 12 and 24 h 
of hypothermic preservation in the different solutions 
was assessed after return to normoxic temperature and 
3-day culture and compared to that of hepatocytes seeded 
directly after isolation.
In these experiments, fresh (FIHs) and cold-preserved 
hepatocytes were seeded based on their viability to estab-
lish a confluent cell monolayer in order to avoid the cell 
dedifferentiation observed in subconfluent human hepa-
tocyte primary cultures (21,27). Q-PCR analysis (Fig. 
2A) revealed that the mRNA expression of HNF1a, 
HNF4a, C/EBPa and C/EBPb (liver-enriched transcrip-
tion factors that are critical for the highly differentiated 
hepatocyte phenotype and function) was well maintained 
after 12 h of cold storage. After 24 h, a slight, but not 
significant, decrease (due to the interindividual variabil-
ity among liver donors) compared to FIHs was observed. 
Similarly, the ability of FIHs and cold-stored hepatocytes 
to synthesize and secrete coagulation factor VII and urea 
(the clinical biological parameters usually followed in 
patients with liver disease) in the extracellular medium 
after 3 days of culture was preserved, but albumin secre-
tion was significantly decreased after 24 h of cold stor-
age (Fig. 2B). Overall, these results demonstrate that 
cold preservation up to 12 h does not dramatically affect 
the phenotype and synthetic functions of human hepato-
cytes in primary culture, regardless of the preservative 
solution used.
Transplantation of Cold-Preserved Human Hepatocytes
We then investigated whether cold-preserved hepato-
cytes in IGL-1 and HTS-FRS solutions could be used for 
cell transplantation. For this purpose, we used a simplified 
mouse model of liver injury (32) that relies on the rapid 
induction of liver damage in a temporally controlled man-
ner following a single intraperitoneal injection of GCV at 
high dose in immunodeficient mice infected with AdTk. 
The experimental protocol is described in Figure 3A.
In this pilot study, two independent transplantation 
experiments (Experiment I: mice with mild liver dam-
age—ALT mean value between 300 and 450 IU/ml; 
Experiment II: mice with sustained liver damage—ALT 
mean value between 500 and 800 IU/ml) were carried out. 
For each experiment, hepatocytes from a single liver were 
used after cold storage in IGL-1 or HTS-FRS (one group 
of mice for each solution; three to seven mice/group) or 
after culture (only for Experiment II). Hepatocyte viability 
FACING PAGE
Figure 3. Engraftment of cold-preserved human hepatocytes in mice infected with AdTk after induction of mild liver damage by 
injection of ganciclovir. (A) Schematic of the transplantation experiments: immunodeficient mice infected with adenoviruses express-
ing thymidine kinase (AdTk) received intraperitoneally a single high dose of ganciclovir as soon as the human liver perfusion was 
planned. Isolated human hepatocytes were cultured or preserved in suspension (1 × 106 cells/ml) on ice in the different solutions 
(IGL-1 and HTS-FRS) and shipped to the transplantation site in Pamplona, Spain. They were injected in the spleen of mice with mild 
(Experiment I) or sustained (Experiment II) liver damage 13 to 15 h after liver dissociation and cold preservation or after a 7-day 
culture period (D7). Human hepatocyte engraftment was evaluated by measuring the production/secretion of human albumin in the 
serum of recipient mice at different time points after transplantation (3 to 9 weeks) in Experiment I (B) and Experiment II (C). Values 
are the mean albumin concentration per group.
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after cold storage at the time of the intrasplenic injection 
(T0) ranged between 62% and 70%, corresponding to a 
recovery between 72% and 97%, when referred to the FIH 
viability (Table 3). Four mice died from surgical compli-
cations at day 2 postgraft in Experiment I (Table 3). The 
remaining mice survived until sacrifice at week 9 after 
transplantation, whereas some of the animals included 
in Experiment II died around week 5 after transplanta-
tion due to illness related to the liver injury (Table 3). 
Transplantation outcomes of Experiments I and II are 
presented in Figures 3 and 4. Engraftment was monitored 
over time by measuring human albumin in the recipients’ 
blood. Its concentration was very variable, even within 
the same group and in animals that received hepatocytes 
from the same liver. Overall, human albumin serum con-
centration gradually increased between weeks 3 and 9 
posttransplantation. However, it was much lower in ani-
mals included in Experiment I (mild liver injury) (Fig. 3B) 
than in those in Experiment II (high liver injury) (Fig. 3C), 
as expected. The presence of human hepatocytes within 
the host liver was confirmed by assessing the mRNA 
expression of several human hepatic markers (Fig. 4A, 
B). Based on the albumin production, hepatocytes that 
had been cold stored in IGL-1 and HTS-FRS showed 
equivalent engraftment capacity in both Experiments I 
and II. Indeed, the levels of circulating human albumin 
increased in a comparable manner in both HTS-FR and 
IGL-1 groups, reaching around 20 µg/ml and 720 µg/ml 
in Experiments I and II, respectively, at the end of the 
experiment (week 9). In contrast, human albumin produc-
tion by human hepatocytes transplanted after 7 days in 
culture (D7) was significantly lower and remained stable 
over time (Fig. 3C). Repopulation of mouse livers by 
human hepatocytes was evaluated also by immunohis-
tochemistry on a small number of animals (Fig. 4C). Five 
weeks after cell graft, human hepatocytes could be iden-
tified with antibodies against human albumin and CK18 
(data not shown) in the liver lobes. They were organized 
in small clusters, reflecting their selective expansion after 
successful engraftment. Four weeks later (9 weeks after 
transplantation), the clusters of human hepatocytes were 
larger, suggesting several rounds of cell division in a sub-
set of transplanted cells. At this stage, in H&E-stained 
sections, clusters of human hepatocytes could be clearly 
differentiated from mouse hepatocytes by their size and 
the paler cytoplasm, as previously described (31,32,48). 
Native regenerative nodules were also visible (Fig. 4C). 
Human hepatocytes were not found in the lungs, and only 
some residual hepatocytes were observed in the spleen 
(Fig. 4D), especially after injection of D7 hepatocytes, 
as revealed by the detection of human hepatic markers in 
this organ (Fig. 4B). In conclusion, cold-preserved human 
FACING PAGE
Figure 4. Analysis of chimeric livers in AdTk/GCG-treated mice after transplantation of cold-preserved or cultured human hepato-
cytes. Human hepatocyte engraftment was evaluated at 9 weeks posttransplantation at the end of Experiment I (A) and Experiment 
II (B) by semiquantitative RT-PCR analysis of the expression of human hepatic genes in the liver, spleen, lung, and muscle. Human–
mouse RNA solutions containing decreasing percentages (from 100% to 1%) of human mRNA were included to estimate the human/
mouse liver chimerism. (C) Immunohistochemistry was performed to specifically detect human CK18 (hCK18) and albumin (hAlb) 
in chimeric livers. The presence of growing human hepatocyte nodules was evidenced at week 9 posttransplantation. Native regenera-
tive nodules were observed after hematoxylin and eosin (H&E) staining. Scale bar: 100 µm. (D) Dissemination of the infused human 
hepatocytes in the recipients’ body was investigated after sacrifice at the end of the experiment (9 weeks posttransplantation) by immu-
nohistochemistry with antibodies against human CK18 in lung, muscle, and spleen tissue sections. Scale bar: 1 mm.
Table 3. Transplantation of Cold-Preserved Human Hepatocytes to Rescue Mice With Liver Failure
Human Hepatocytes (Viability)
Transplanted Mice Survivors 
(Day/Week of Sacrifice)
Hepatocytes Experiment I Experiment II Experiment I (n = 7) Experiement II (n = 3)
Fresh 72 ± 4% 86 ± 2 % – –
Cold-stored
IGL-1 62 ± 7.7% 62 ± 5 % 5/7 (day 2) 5/7 (9 weeks) 3/3 (9 weeks)
HTS-FRS 70 ± 1.7% 66 ± 4.4 % 5/7 (day 2) 5/7 (9 weeks) 1/3 (9 weeks)
Cultured
Day 7 – 85% – 3/3 (9 weeks)
Control – – 2/2 (9 weeks) 3/3 (9 weeks)
Hepatocyte viability and mice survival outcomes in two independent transplantation experiments (Experiments I and 
II). For each experiment, hepatocytes from one single liver were used. Ratios refer to the number of surviving mice/
total number of mice at the time point indicated in parentheses.
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hepatocytes retain their ability to engraft and repair a 
damaged liver, whatever the preservative solution, and 
display normal biological functions, as shown by the 
albumin production over a 9-week period after transplan-
tation. Cultured human hepatocytes can also engraft and 
proliferate in damaged livers, as previously shown (32), 
but not as efficiently as cold-preserved hepatocytes.
DISCUSSION
The objectives of this study were to evaluate hypo-
thermic conditions for preserving FIHs in clinically safe 
preservative solutions and then to determine whether and 
to what extent cold-stored hepatocytes can repopulate a 
damaged liver in a mouse model.
Plating efficiency is a valuable criterion of cell vitality 
and is assumed to correlate with their engraftment capacity 
in the liver. As described by others, we found that viability 
and attachment of human hepatocytes after hypothermic 
storage in suspension were dependent on cell density and 
on the preservation period. After short hypothermic storage 
(12 h), hepatocytes in primary culture were as healthy and 
functional as freshly isolated cells. Previous studies reported 
comparable gene expression profiles (44) and xenobiotic 
metabolism capacity and clearance predictions in human 
hepatocytes in suspension after cold storage and in freshly 
isolated cells (19,36). We found that human hepatocytes 
could be cold stored at 4°C for up to 24 h without signifi-
cant decrease in functional integrity, as assessed by their 
ability to attach on a substratum and to produce and secrete 
urea and factor VII, and with a viability higher than 60%, 
which is the threshold limit value currently accepted as an 
insurance of hepatocyte quality for biotherapy programs 
(1). Moreover, we did not observe any clear specific effect 
of the three storage solutions, although IGL-1 and HTS-
FRS seemed to give better results than UW concerning cell 
survival. These results are in agreement with recent data 
showing the superiority of HTS-FRS compared to UW for 
the maintenance of the metabolic activity of human hepa-
tocytes in vitro after 48 h and 72 h of cold storage (36). 
However, in our study the difference between UW and 
HTS-FRS was not as significant as in this previous work. 
Our results are similar to those reported by Gramignoli et 
al. showing that critical hepatic functions, analyzed in 47 
human hepatocyte preparations, were well maintained in 
hepatocytes after cold storage in UW solution for up to 48 
h, although in our hands UW is not as performing as stated 
in this work (19). The metabolic activity of animal hepato-
cytes also was reported to be maintained after cold storage 
in UW solution for 48 h (35). These discrepancies could 
be related to the age, underlying pathology and medication 
taken by the liver donors, the impact of the ischemic time 
on the liver samples and/or species differences (22), and 
also to the cell dissociation and isolation procedures (col-
lagenases and proteases ratio and activities, composition 
of the perfusion buffers) that can impact on cell conserva-
tion methods (20,34, and unpublished data). Concerning 
the IGL-1 solution, no other data are currently available 
regarding its ability to preserve the viability and function-
ality of human or animal hepatocytes.
Although we observed a decrease in cell viability 
after 24 h of cold storage, it has to be noted that impor-
tant synthetic activities required for clinical applications, 
such as urea synthesis and factor VII secretion, were still 
well maintained in the surviving cells after 3 days in cul-
ture. Urea synthesis, a complex process involving several 
enzymes, is a good indicator of the degree of mitochon- 
drial preservation. Like others, we found that urea metab-
olism is better maintained than albumin secretion, which 
seems more sensitive to long-term cold preservation 
(19). This could be related to the irreversible cytoskel-
eton disorganization that is associated with long-term 
cooling and rewarming and that affects the cell transport 
dynamics (25,46).
We then evaluated to which extent cold preserva-
tion in IGL-1 and HTS-FRS solutions influences human 
hepatocyte survival and function after transplantation 
into a suitable animal model. Comparison with freshly 
isolated cells was not included because our intent was to 
simulate the clinical situation that occurs when hepato-
cytes are prepared in specialized centers far away from 
the transplantation site. For the same reason, the chosen 
mouse model of AdTk/GCV-induced liver damage (32) 
was very convenient for performing on-demand trans-
plantation studies, as the availability of human livers is 
unpredictable. Using this experimental model, we show 
that human hepatocytes can survive, engraft, and prolifer-
ate in a chronically damaged liver after cold preservation 
in IGL-1 and HTS-FRS solutions. Although it is difficult 
to measure the exact extent of the contribution of human 
hepatocytes in the chimeric mouse liver, we think that 
about 10–15% of hepatocytes were of human origin based 
on the expression of human-specific liver function mark-
ers (by immunohistochemistry and RT-PCR analysis) in 
the liver of the recipient mice. This estimation is in accor-
dance with the data by Hasegawa et al. (23) showing a 
high correlation between liver chimerism and plasma con-
centration of human albumin in recipient mice. Although 
preliminary (due to the small number of animals included 
in the study), our data suggest that IGL-1 and HTS-FRS 
represent alternative conservative solutions useful for bio-
therapy programs based on hepatocyte transplantation.
IGL-1 previously showed some level of protection 
against the immune response following kidney and pan-
creatic islet grafts, possibly due to the “immunocam-
ouflage” provided by PEG interaction with membranes 
(50). Moreover, according to Ben Mosbah et al., IGL-1 
offers a better protection to steatotic livers, which are 
the main available source of human hepatocytes for 
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liver biotherapy, against the deleterious effects of cold 
ischemia–reperfusion injury than the UW solution (5). 
Whether these protective effects are also effective on 
hepatocytes isolated from such livers is an interesting 
question that deserves further studies.
Compared to cryopreservation, hypothermia is a 
milder technique that does not require the use of poten-
tially deleterious chemicals, liquid nitrogen, or special 
equipment for cell storage and might allow shipping 
to remote sites for transplantation. Its main disadvan-
tage is the relatively short period of time that cells can 
be preserved. However, recent advances in preservation 
methods based either on supercoiling (51) or on the for-
mulation of new solutions better adapted to cold storage 
has already allowed increasing the preservation time of 
rat hepatocytes up to 1 week with improved cell survival 
and function (8,40). The application of these strategies 
to the preservation of primary human hepatocytes has 
already given some promising results (39). Hepatocytes 
may also be preserved by culturing. We show here that 
our long-term culture conditions favor human hepatocyte 
survival in monolayer (7,14,18,38,52) and also maintain 
their ability to engraft and proliferate in a damaged liver 
microenvironment. However, engraftment and prolifera-
tion were less efficient than after cold storage in suspen-
sion. Moreover, the culture process introduces additional 
steps that may increase cell loss after detachment, eco-
nomic cost, and safety concerns.
In conclusion, we show that primary human hepato-
cytes can be hypothermically preserved up to 24 h while 
maintaining a metabolic activity similar to that of freshly 
isolated cells. This cheap procedure, based on clinically 
safe and commonly used preservative solutions, allows 
the easy handling of large quantities of hepatocytes iso-
lated from precious donor livers, optimizing their use in 
clinical biotherapy programs. Indeed, cold preservation 
gives the time to deliver cells to distant transplantation 
centers and facilitates their repeated use when several cell 
infusions or refilling of an extracorporal bioartificial liver 
bioreactor are required. Overall, our results demonstrate 
that human hepatocytes could be successfully cold pre-
served in clinically safe and commonly used preservative 
solutions for clinical applications.
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